JPRN-UMIN000035020已完成1 期
Safety assessment of neoantigen peptides-loaded dendritic cell vaccination therapy. - Vaccination with neoantigen-loaded DCs
Bio-Thera Clinic0 个研究点目标入组 19 人开始时间: 2018年11月27日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 19
研究概览
简要总结
eoantigen DCs would be a safe treatment method. Neoantigen DCs would induce the acquisition of immune reaction against neoantigens.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 12years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •A patient must not: - be impossible to obtain blood sample by Leukapeheresis. - be positive in HIV antibody test. - have active auto-immune disorder. - have serious underlying disease. - be pregnant (including pregnancy seeker) - be judged ineligibles by clinician in this trial.
研究者
相似试验
已完成
2 期
Safety assessment of neoantigen peptides-loaded dendritic cell vaccination therapy.Malignant tumor (except leukemia)JPRN-jRCTc030190183Tanigawa Keishi20
招募中
1 期
Neoantigen Derived DCs as Cancer TreatmentRefractory TumorSolid TumorNCT05767684National Health Research Institutes, Taiwan12
Unknown
1 期
Personalized DC Vaccine for Lung CancerCarcinoma, Non-Small-Cell LungNCT02956551Sichuan University20
招募中
1 期
Personalized DC Vaccine for Postoperative CancerNon-Small-Cell Lung CancerColon Rectal CancerHepatocellular CarcinomaGastric CancerNCT04147078Sichuan University80
招募中
不适用
Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT05000801Affiliated Hospital to Academy of Military Medical Sciences20